
*.- Updated: 2014_01_31 .
*.- Study Start Date: June 2010 .
*.- Estimated Study Completion Date: June 2014 .
*.- Estimated Primary Completion Date: June 2014 (Final data collection date for primary outcome measure) .
EUROPA PASA DE TENER DOS TRATAMIENTOS SCLC-ES EN PRIMERA LINEA INMUNOTERAPIA ( ATEZOLIZUMAB Y DURVALUMAB ) ... A TENER CUATRO ( ATEZOLIZUMAB, DURVALUMAB , SERPLULIMAB Y TISLELIZUMAB ) .